In our study of 545 patients with indications of MPN, JAK2 was the most frequently mutated gene (23% of patients) followed by TET2 (12%) and ASXL1 (10%), frequencies similar to literature [51, 52]. This evidence concerns the gene ASXL1 and myeloproliferative disorder.